Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with FOLFOX or FOLFIRI for Colorectal Cancer Metastases
NCT01858649Phase 2Completed
- Start
- May 2013
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (metastatic) (mCRC). Started May 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01858649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858649.